Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements review observed that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://williamk108oec7.blogchaat.com/profile